X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11357) 11357
Newsletter (405) 405
Book Chapter (48) 48
Newspaper Article (48) 48
Dissertation (19) 19
Magazine Article (13) 13
Publication (4) 4
Government Document (3) 3
Book / eBook (2) 2
Conference Proceeding (2) 2
Reference (2) 2
Streaming Video (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bortezomib (10478) 10478
humans (7465) 7465
multiple myeloma (4099) 4099
oncology (3928) 3928
hematology (3235) 3235
male (3048) 3048
female (2984) 2984
multiple myeloma - drug therapy (2792) 2792
middle aged (2438) 2438
aged (2228) 2228
cancer (2067) 2067
apoptosis (1942) 1942
dexamethasone (1713) 1713
animals (1665) 1665
antineoplastic agents - therapeutic use (1622) 1622
antineoplastic combined chemotherapy protocols - therapeutic use (1611) 1611
adult (1590) 1590
treatment outcome (1589) 1589
boronic acids - therapeutic use (1535) 1535
pyrazines - therapeutic use (1523) 1523
boronic acids - pharmacology (1505) 1505
cell line, tumor (1496) 1496
pyrazines - pharmacology (1479) 1479
proteasome inhibitors (1474) 1474
therapy (1447) 1447
chemotherapy (1435) 1435
antineoplastic agents - pharmacology (1307) 1307
multiple-myeloma (1297) 1297
boronic acids - administration & dosage (1236) 1236
pyrazines - administration & dosage (1233) 1233
lenalidomide (1228) 1228
care and treatment (1207) 1207
survival (1174) 1174
research (1163) 1163
apoptosis - drug effects (1147) 1147
thalidomide (1131) 1131
multiple myeloma - pathology (1024) 1024
transplantation (1024) 1024
mice (989) 989
stem-cell transplantation (962) 962
aged, 80 and over (910) 910
prognosis (817) 817
drug therapy (806) 806
dexamethasone - administration & dosage (784) 784
expression (783) 783
thalidomide - analogs & derivatives (767) 767
proteins (751) 751
analysis (742) 742
multiple myeloma - therapy (733) 733
multiple myeloma - mortality (700) 700
pharmacology & pharmacy (700) 700
combination (692) 692
proteasome endopeptidase complex - metabolism (692) 692
proteasome inhibitor bortezomib (690) 690
proteasome (677) 677
boronic acids - adverse effects (675) 675
pyrazines - adverse effects (673) 673
nf-kappa-b (649) 649
cell biology (642) 642
activation (636) 636
stem cells (624) 624
thalidomide - administration & dosage (619) 619
proteasome inhibitor (614) 614
health aspects (613) 613
hemic and lymphatic diseases (601) 601
antineoplastic agents - adverse effects (588) 588
recurrence (585) 585
antineoplastic combined chemotherapy protocols - adverse effects (584) 584
cells (582) 582
patients (582) 582
myeloma (581) 581
medicine & public health (566) 566
antineoplastic agents - administration & dosage (543) 543
cell proliferation - drug effects (542) 542
hematology, oncology and palliative medicine (542) 542
retrospective studies (542) 542
dose-response relationship, drug (539) 539
biochemistry & molecular biology (538) 538
thalidomide - therapeutic use (535) 535
abridged index medicus (533) 533
melphalan (532) 532
disease-free survival (525) 525
bortezomib - therapeutic use (521) 521
proteasome inhibitors - pharmacology (520) 520
trial (511) 511
drug synergism (510) 510
multiple myeloma - genetics (509) 509
multiple myeloma - diagnosis (494) 494
bortezomib - pharmacology (488) 488
clinical trials (486) 486
drug resistance, neoplasm (485) 485
immunology (484) 484
dosage and administration (479) 479
bortezomib - administration & dosage (477) 477
rituximab (475) 475
protease inhibitors - pharmacology (473) 473
multiple myeloma - metabolism (470) 470
stem cell transplantation (466) 466
cyclophosphamide (465) 465
protease inhibitors - therapeutic use (462) 462
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11368) 11368
Chinese (226) 226
Japanese (133) 133
German (92) 92
French (86) 86
Russian (49) 49
Spanish (44) 44
Czech (42) 42
Polish (42) 42
Korean (18) 18
Hungarian (15) 15
Italian (15) 15
Turkish (7) 7
Norwegian (5) 5
Portuguese (5) 5
Slovenian (4) 4
Danish (2) 2
Croatian (1) 1
Dutch (1) 1
Persian (1) 1
Serbian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Life Sciences | Cancer
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2016, Volume 113, Issue 46, pp. 13162 - 13167
Journal Article
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2016, Volume 13, Issue 3, pp. 885 - 896
Abstract The development of resistance and subsequent metastasis makes prostate cancer a leading cause of cancer-related death among men. Hence,... 
Internal Medicine | Bortezomib | Zein nanoparticles | Prostate cancer | Vorinostat | MEDICINE, RESEARCH & EXPERIMENTAL | GRAPHENE OXIDE | LIPID NANOPARTICLES | ANDROGEN RECEPTOR | CELLS | DRUG-DELIVERY | NANOSCIENCE & NANOTECHNOLOGY | RELEASE | BREAST-CANCER | LIQUID-CRYSTALLINE NANOPARTICLES | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nanoparticles - chemistry | Apoptosis - drug effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Histone Deacetylase Inhibitors - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Bortezomib - pharmacology | Drug Carriers - chemistry | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Histone Deacetylase Inhibitors - pharmacokinetics | Prostate - pathology | Neoplasm Metastasis - drug therapy | Hydroxamic Acids - administration & dosage | Prostate - drug effects | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Hydroxamic Acids - pharmacology | Prostatic Neoplasms - drug therapy | Proteasome Inhibitors - pharmacokinetics | Prostatic Neoplasms - pathology | Proteasome Inhibitors - pharmacology | Proteasome Inhibitors - administration & dosage | Nanoparticles - ultrastructure | Proteasome Inhibitors - therapeutic use | Hydroxamic Acids - pharmacokinetics | Drug Synergism | Particle Size | Cell Movement - drug effects | Animals | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - therapeutic use | Mice, Nude | Neoplasm Metastasis - pathology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Zein - chemistry | Histone Deacetylase Inhibitors - therapeutic use | Mice, Inbred BALB C | Bortezomib - pharmacokinetics | Proteins | Nanoparticles | Care and treatment | Metastasis | Cancer | Pharmacy | Drugstores | Index Medicus
Journal Article
Blood, ISSN 1528-0020, 2017, Volume 130, Issue 22, pp. 2392 - 2400
Journal Article
Revue du rhumatisme (Ed. française : 1993), ISSN 1169-8330, 2019, Volume 86, Issue 4, pp. 398 - 399
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2017, Volume 145, Issue 2, pp. 236 - 242
Abstract Purpose Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced,... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Intraperitoneal | Platinum | Proteasome inhibition | Ovarian cancer | SOLID TUMORS | LONG-TERM SURVIVAL | COMBINATION | CHEMOTHERAPY | PACLITAXEL | OBSTETRICS & GYNECOLOGY | TRIAL | STAGE-III OVARIAN | CISPLATIN | ONCOLOGY | HYPERSENSITIVITY REACTIONS | PROTEASOME INHIBITOR | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Neoplasms, Glandular and Epithelial - metabolism | Carboplatin - pharmacokinetics | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Neoplasms, Glandular and Epithelial - blood | Adult | Female | Ovarian Neoplasms - metabolism | Bortezomib - blood | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Neoplasm Recurrence, Local - metabolism | Carboplatin - administration & dosage | Carboplatin - blood | Infusions, Parenteral | Ovarian Neoplasms - blood | Bortezomib - administration & dosage | Bortezomib - adverse effects | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Aged | Bortezomib - pharmacokinetics | Care and treatment | Relapse | Bortezomib | Oncology, Experimental | Clinical trials | Research | Cancer | Diseases | Prevention | Index Medicus
Journal Article